1 / 16

Tacrolimus and Pimecrolimus and Risk Of Malignancy

Elizabeth Gorevski Kingsbrook Jewish Medical Center Brooklyn, NY. Tacrolimus and Pimecrolimus and Risk Of Malignancy. Uses of Tacrolimus and Pimecrolimus. Munzenberger P et al Pharmacotherapy 2007; 27(7). Treating Atopic Dermatitis.

valiant
Download Presentation

Tacrolimus and Pimecrolimus and Risk Of Malignancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Elizabeth Gorevski Kingsbrook Jewish Medical Center Brooklyn, NY Tacrolimus and Pimecrolimus and Risk Of Malignancy

  2. Uses of Tacrolimus and Pimecrolimus Munzenberger P et al Pharmacotherapy 2007; 27(7)

  3. Treating Atopic Dermatitis International Consensus Conference on Atopic Dermatitis II (ICCAD II) and American Academy of Dermatology (AAD) Pimecrolimus cream 1% - a second-line therapy of mild – moderate atopic dermatitis Tacrolimus ointment 0.03% - moderate – severe atopic dermatitis that inadequately responds to other topicals In children 3-5 only use tacrolimus 0.03% Munzenberger P et al Pharmacotherapy 2007; 27(7)

  4. Mechanism of Action Mirsland A. et al Euro J Derm 2002;12(6)

  5. Boxed Warning of Tacrolimus and Pimecrolimus Casual relationship has not been established

  6. Why concerns? • Increased risk of malignancies with systemic immunosuppression after long term-high dose for graft rejection in transplant patients • Oral tacrolimus associated with posttranslational lymphoproliferative disease • Occurs in first 8 months after stem cell transplant in 0.7% of population receiving related donor human leukocyte antigen matched transplants • Animal studies show carcinogenicity Yarosh D, et al J Invest Dermatol 2005; 125

  7. Pharmacokinetic Data for Topical Pimecrolimus and Tacrolimus Pharmacokinetic studies with PO and IV tacrolimus Concentrations achieved PO : 82.7 ng/mL (0.075 mg/kg/12 hours) IV : 3300 ng/mL (0.05 mg/kg/12 hours) Sanchez-Perez J at al. Actas Derm 2007; 98

  8. Agents Plasma Concentrations • Pimecrolimus • Used twice daily led to blood concentrations < 0.5 – 1 ng/mL • Higher concentrations in patients with more extensive disease  Netherton syndrome • In transplant patients the systemic administrations has been increased rate of lymphomas, nonmelanoma skin cancer and melanomas in sun exposed areas • Plasma concentrations are much lower with topical application then systemic when used in plasma patients Arellano F. et al J Invest Derm 2007; 127

  9. Lymphomas • No evidence of increased prevalence of lymphomas associated with short term, intermittent topical application • According to clinical trials • No observed lymphomas in close to 10,000 patients with tacrolimus • Only 2 cases of solid tumors in 25,000 patients treated with pimecrolimus • Pharmacovigilance data • Compared with general population following marketing no increased risk of lymphoma in close to 7 million prescriptions of pimecrolimus and 2 million prescriptions of topical tacrolimus • Systemic administration • Posttransplant lymphoproliferative disease ranges from 2% - 60 % in patient and is most common with small intestant transplant • Lymphomas regress spontaneously upon discontinuation of therapy in 30% - 50 % of cases Arellano F. et al J Invest Derm 2007; 127

  10. Skin Cancer • Clinical trials • 13 cases of nonmalenoma skin cancer, 10 basal cell epithelimas and 3 sqamous cell carcinomas observed in 10,000 patients treated • FDA report in December 2004 • 10 cases of skin tumors in patients treated with tacrolimus • 6 cases of basla and sqamous cell carcinomas in patients treated with pimecrolimus • In subsequent publications number increased to 21 cases • Prospective study of 9813 patients with atopic dermatitis for 208 days • No increase was in nonmelanoma cancer was observed when 0.1% and 0.003% tacrolimus cream was used Arellano F. et al J Invest Derm 2007; 127

  11. A Cohort Analysis • 293, 253 patients • 58.6% < 20 years old • Almost 60% female • 20% met criteria for severe atopic dermatitis • Topical agents at follow up • 40% used topical steroids • 7.4% pimecrolimus • 13.7% tacrolimus • 0.9% to pimecrolimus and tacrolimus • Almost half of patients did not use medications • Most patients were enrolled in database from 2001 onward • Atopic dermatitis was diagnosed by family physician, pediatrician or dermatologist Arellano F. et al J Invest Derm 2007; 127

  12. Exposure to Medication and Risk of Lymphoma Arellano F. et al J Invest Derm 2007; 127

  13. Risk of Lymphoma According to Age Arellano F. et al J Invest Derm 2007; 127

  14. International Consensus

  15. Conclusions • Pharmacokinetics data do not suggest that TCI affect the systemic immune system, as their oral counterparts • There is no data associated with an increased risk of lymphoproliferative disease with topical tacrolimus and pimecrolimus • Short term efficacy and safety data was demonstrated in clinical trials and post-surveillance in approximately 11 million patients • Several professional and patient organization are supporting safety, with close monitoring • Box warning itself states no casual link between TCI and malignancy • Post marketing surveillance for at least 8 – 10 years is required to ensure safety

  16. Application to Pharmacists

More Related